AtriCure Company Profile (NASDAQ:ATRC)

About AtriCure (NASDAQ:ATRC)

AtriCure logoAtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:ATRC
  • CUSIP: 04963C20
  • Web: www.atricure.com
Capitalization:
  • Market Cap: $748.14 million
  • Outstanding Shares: 34,334,000
Average Prices:
  • 50 Day Moving Avg: $21.90
  • 200 Day Moving Avg: $21.44
  • 52 Week Range: $14.78 - $25.18
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -30.97
  • P/E Growth: -1.15
Sales & Book Value:
  • Annual Revenue: $166 million
  • Price / Sales: 4.55
  • Book Value: $4.70 per share
  • Price / Book: 4.68
Profitability:
  • EBIDTA: ($19,620,000.00)
  • Net Margins: -19.56%
  • Return on Equity: -19.56%
  • Return on Assets: -11.91%
Debt:
  • Debt-to-Equity Ratio: 0.21%
  • Current Ratio: 2.56%
  • Quick Ratio: 1.93%
Misc:
  • Average Volume: 184,802 shs.
  • Beta: 0.85
  • Short Ratio: 13.26
 

Frequently Asked Questions for AtriCure (NASDAQ:ATRC)

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) issued its quarterly earnings results on Thursday, July, 27th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.26) by $0.05. The company had revenue of $45.23 million for the quarter, compared to analyst estimates of $44.15 million. AtriCure had a negative net margin of 19.56% and a negative return on equity of 19.56%. The business's revenue for the quarter was up 14.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.26) earnings per share. View AtriCure's Earnings History.

When will AtriCure make its next earnings announcement?

AtriCure is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for AtriCure.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure updated its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $(1.04)-(0.94) for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.96). The company issued revenue guidance of $177-178 million, compared to the consensus revenue estimate of $175.85 million.

Where is AtriCure's stock going? Where will AtriCure's stock price be in 2017?

7 brokers have issued 12-month price targets for AtriCure's stock. Their predictions range from $22.00 to $26.00. On average, they anticipate AtriCure's stock price to reach $24.83 in the next twelve months. View Analyst Ratings for AtriCure.

What are analysts saying about AtriCure stock?

Here are some recent quotes from research analysts about AtriCure stock:

  • 1. Needham & Company LLC analysts commented, "ATRC’s 2Q17 revenue, EBITDA, and EPS beat consensus and management raised its 2017 revenue guidance. Worldwide Open-Heart Ablation growth improved to 11% from 10% in 1Q17 and US Open-Heart Ablation growth improved to 14% from 12% in 1Q17. We think that the accelerating Open-Heart growth should help to reduce concerns that this business is in a permanent slowdown and we think this shows that the new guidelines for ablation in concomitant open-heart procedures are driving stronger growth in this business. ATRC shares remain at a large discount to peers (2017E EV/sales of 4.4x vs. small/mid-cap growth peers at a median of 7.1x) and we reiterate our Buy rating." (7/28/2017)
  • 2. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (5/10/2017)

Who are some of AtriCure's key competitors?

Who are AtriCure's key executives?

AtriCure's management team includes the folowing people:

  • Richard M. Johnston, Independent Chairman of the Board
  • Michael H. Carrel, President, Chief Executive Officer, Director
  • M. Andrew Wade CPA, Chief Financial Officer, Senior Vice President
  • Douglas J. Seith, Chief Operating Officer
  • Justin J. Noznesky, Senior Vice President, Marketing and Business Development
  • Andrew L. Lux Ph.D., Senior Vice President -Operations and Quality
  • Salvatore Privitera, Chief Technology Officer
  • Mark A. Collar, Independent Director
  • Scott William Drake, Independent Director
  • Regina E. Groves, Independent Director

Who owns AtriCure stock?

AtriCure's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (14.76%), Vanguard Group Inc. (4.21%), Victory Capital Management Inc. (3.84%), First Light Asset Management LLC (2.79%), Peregrine Capital Management LLC (2.63%) and Neuberger Berman Group LLC (2.40%). Company insiders that own AtriCure stock include Andrew L Lux, Douglas J Seith and Elizabeth D Krell. View Institutional Ownership Trends for AtriCure.

Who sold AtriCure stock? Who is selling AtriCure stock?

AtriCure's stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC, Peregrine Capital Management LLC, Wells Fargo & Company MN, Osterweis Capital Management Inc., Emerald Advisers Inc. PA, Lockheed Martin Investment Management Co., Wasatch Advisors Inc. and Paradigm Asset Management Co. LLC. Company insiders that have sold AtriCure stock in the last year include Andrew L Lux and Elizabeth D Krell. View Insider Buying and Selling for AtriCure.

Who bought AtriCure stock? Who is buying AtriCure stock?

AtriCure's stock was acquired by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, FMR LLC, Vanguard Group Inc., Marshall Wace North America L.P., Royce & Associates LP, Parametric Portfolio Associates LLC, State Street Corp and Essex Investment Management Co. LLC. View Insider Buying and Selling for AtriCure.

How do I buy AtriCure stock?

Shares of AtriCure can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AtriCure's stock price today?

One share of AtriCure stock can currently be purchased for approximately $21.99.


MarketBeat Community Rating for AtriCure (NASDAQ ATRC)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  248 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  355
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AtriCure (NASDAQ:ATRC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $24.83 (12.93% upside)

Analysts' Ratings History for AtriCure (NASDAQ:ATRC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/30/2017Stifel NicolausReiterated RatingBuy$25.00MediumView Rating Details
7/28/2017Needham & Company LLCReiterated RatingBuy -> Buy$25.00 -> $26.00HighView Rating Details
6/16/2017Leerink SwannReiterated RatingOutperform$26.00LowView Rating Details
5/30/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$26.00LowView Rating Details
4/17/2017Canaccord GenuityReiterated RatingBuy$22.00LowView Rating Details
3/20/2017Northland SecuritiesReiterated RatingBuy$24.00LowView Rating Details
3/6/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
8/6/2016JMP SecuritiesSet Price TargetBuy$23.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for AtriCure (NASDAQ:ATRC)
Earnings by Quarter for AtriCure (NASDAQ:ATRC)
Earnings History by Quarter for AtriCure (NASDAQ ATRC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017($0.21)N/AView Earnings Details
7/27/2017Q2 2017($0.26)($0.21)$44.15 million$45.23 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.33)($0.32)$40.25 million$41.30 millionViewListenView Earnings Details
2/28/2017Q4 2016($0.32)($0.27)$41.17 million$41.20 millionViewListenView Earnings Details
10/27/2016Q316($0.28)($0.21)$10.75 million$38.34 millionViewListenView Earnings Details
8/4/2016Q216($0.30)($0.26)$39.84 million$39.70 millionViewListenView Earnings Details
4/28/2016Q116($0.32)($0.31)$36.08 million$35.90 millionViewListenView Earnings Details
2/23/2016Q415($0.36)($0.36)$35.90 million$35.90 millionViewListenView Earnings Details
10/27/2015Q315($0.22)($0.22)$31.32 million$31.40 millionViewListenView Earnings Details
7/28/2015Q215($0.21)($0.18)$30.51 million$32.58 millionViewListenView Earnings Details
4/29/2015Q115($0.21)($0.19)$28.65 million$29.90 millionViewListenView Earnings Details
2/23/2015Q414($0.20)($0.20)$28.40 million$29.40 millionViewListenView Earnings Details
10/30/2014Q314($0.17)($0.02)$25.60 million$26.70 millionViewListenView Earnings Details
7/24/2014Q214($0.19)($0.10)$25.03 million$26.51 millionViewListenView Earnings Details
4/24/2014Q114($0.22)($0.31)$23.36 million$24.80 millionViewListenView Earnings Details
2/27/2014Q413($0.14)($0.24)$21.16 million$21.90 millionViewListenView Earnings Details
10/29/2013Q313($0.15)($0.13)$18.30 million$20.10 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.10)($0.09)$19.42 million$20.40 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.09)($0.10)$18.63 million$19.43 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.09)($0.12)$18.46 million$18.40 millionViewListenView Earnings Details
11/1/2012Q312($0.11)($0.16)$17.29 million$16.10 millionViewN/AView Earnings Details
8/2/2012($0.07)($0.08)ViewN/AView Earnings Details
5/2/2012($0.13)($0.10)ViewN/AView Earnings Details
11/1/2011($0.07)($0.07)ViewN/AView Earnings Details
8/2/2011($0.01)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AtriCure (NASDAQ:ATRC)
2017 EPS Consensus Estimate: ($1.09)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.37)($0.37)($0.37)
Q2 20171($0.29)($0.29)($0.29)
Q3 20171($0.23)($0.23)($0.23)
Q4 20171($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AtriCure (NASDAQ:ATRC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for AtriCure (NASDAQ:ATRC)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 82.07%
Insider Trades by Quarter for AtriCure (NASDAQ:ATRC)
Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)
Insider Trades by Quarter for AtriCure (NASDAQ:ATRC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2017Elizabeth D KrellDirectorSell10,000$22.40$224,000.00View SEC Filing  
5/17/2017Elizabeth D KrellDirectorSell10,000$21.44$214,400.00View SEC Filing  
3/17/2017Andrew L LuxSVPSell20,000$18.85$377,000.00View SEC Filing  
11/15/2016Elizabeth D KrellDirectorSell10,000$19.73$197,300.00View SEC Filing  
9/13/2016Elizabeth D KrellDirectorSell6,000$15.93$95,580.00View SEC Filing  
8/17/2016Elizabeth D KrellDirectorSell5,000$15.20$76,000.00View SEC Filing  
3/8/2016Elizabeth D KrellDirectorSell10,000$16.91$169,100.00View SEC Filing  
12/3/2015Douglas J. SeithCOOSell5,000$21.55$107,750.00View SEC Filing  
12/2/2015Elizabeth D. KrellDirectorSell10,000$21.88$218,800.00View SEC Filing  
11/11/2015Elizabeth D. KrellDirectorSell10,000$20.68$206,800.00View SEC Filing  
4/1/2015Michael D HoovenDirectorSell142,268$20.81$2,960,597.08View SEC Filing  
3/31/2015Michael D HoovenDirectorSell20,000$20.51$410,200.00View SEC Filing  
3/30/2015Michael D HoovenDirectorSell85,000$21.01$1,785,850.00View SEC Filing  
3/13/2015Karen P RobardsDirectorSell3,150$19.53$61,519.50View SEC Filing  
3/5/2015Douglas J SeithCOOSell36,688$17.51$642,406.88View SEC Filing  
3/2/2015Elizabeth D KrellDirectorSell10,000$17.63$176,300.00View SEC Filing  
5/6/2014Douglas SeithSVPBuy1,000$15.04$15,040.00View SEC Filing  
9/13/2013Richard JohnstonInsiderSell77,610$10.00$776,100.00View SEC Filing  
8/12/2013Douglas SeithSVPBuy10,000$9.58$95,800.00View SEC Filing  
8/5/2013Richard JohnstonInsiderSell20,047$10.00$200,470.00View SEC Filing  
7/11/2013Richard M JohnstonInsiderSell2,343$10.00$23,430.00View SEC Filing  
6/19/2013Richard M JohnstonInsiderSell29,348$8.96$262,958.08View SEC Filing  
6/18/2013Richard M JohnstonInsiderSell39,682$9.18$364,280.76View SEC Filing  
6/14/2013Richard M JohnstonInsiderSell95,598$8.97$857,514.06View SEC Filing  
6/12/2013Richard M JohnstonInsiderSell35,372$9.01$318,701.72View SEC Filing  
3/6/2013James L LuckyVPSell50,065$8.14$407,529.10View SEC Filing  
9/14/2012Mark R LanningDirectorBuy11,006$7.64$84,085.84View SEC Filing  
9/13/2012Michael D HoovenDirectorBuy1,110$7.37$8,180.70View SEC Filing  
9/12/2012Michael D HoovenDirectorBuy1,150$7.10$8,165.00View SEC Filing  
9/11/2012Michael D HoovenDirectorBuy1,145$7.18$8,221.10View SEC Filing  
9/10/2012Michael D HoovenDirectorBuy1,215$7.15$8,687.25View SEC Filing  
9/7/2012Michael D HoovenDirectorBuy1,215$6.88$8,359.20View SEC Filing  
8/23/2012Karen P RobardsDirectorBuy1,000$6.70$6,700.00View SEC Filing  
8/16/2012Karen P RobardsDirectorBuy1,000$6.98$6,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for AtriCure (NASDAQ:ATRC)
Latest Headlines for AtriCure (NASDAQ:ATRC)
Source:
DateHeadline
americanbankingnews.com logoAtriCure, Inc. (ATRC) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 13 at 10:50 AM
seekingalpha.com logoAtriCure, Inc. (ATRC) Presents at Morgan Stanley 2017 Global Healthcare Conference (Transcript)
seekingalpha.com - September 13 at 2:29 AM
finance.yahoo.com logoAtriCure Announces U.S. Launch of the AtriClip® PRO•V™ Device
finance.yahoo.com - September 12 at 4:24 PM
americanbankingnews.com logoAtriCure (ATRC) & DENTSPLY SIRONA (XRAY) Head to Head Survey
www.americanbankingnews.com - September 9 at 12:20 PM
americanbankingnews.com logoAtriCure, Inc. (ATRC) Expected to Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - August 31 at 8:08 AM
americanbankingnews.com logoHead-To-Head Comparison: Landauer (LDR) versus AtriCure (ATRC)
www.americanbankingnews.com - August 30 at 4:08 AM
americanbankingnews.com logoAtriCure, Inc. (ATRC) Director Sells $224,000.00 in Stock
www.americanbankingnews.com - August 23 at 1:14 PM
americanbankingnews.com logoAtriCure, Inc. (ATRC) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 19 at 11:20 AM
finance.yahoo.com logoAtriCure, Inc. breached its 50 day moving average in a Bullish Manner : ATRC-US : August 15, 2017
finance.yahoo.com - August 15 at 5:06 PM
finance.yahoo.com logoETFs with exposure to AtriCure, Inc. : August 15, 2017
finance.yahoo.com - August 15 at 5:06 PM
americanbankingnews.com logoIntersect ENT (XENT) versus AtriCure (ATRC) Head to Head Review
www.americanbankingnews.com - August 13 at 6:08 AM
americanbankingnews.com logo-$0.24 Earnings Per Share Expected for AtriCure, Inc. (NASDAQ:ATRC) This Quarter
www.americanbankingnews.com - August 12 at 8:10 PM
americanbankingnews.com logoAtriCure, Inc. (ATRC) Downgraded to Sell at BidaskClub
www.americanbankingnews.com - August 5 at 9:56 PM
finance.yahoo.com logoAtriCure, Inc. :ATRC-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017
finance.yahoo.com - August 1 at 5:05 PM
americanbankingnews.com logoAtriCure, Inc. (NASDAQ:ATRC) Given "Buy" Rating at Needham & Company LLC
www.americanbankingnews.com - July 30 at 4:34 PM
americanbankingnews.com logoAtriCure, Inc. (NASDAQ:ATRC) Earns "Buy" Rating from Stifel Nicolaus
www.americanbankingnews.com - July 30 at 10:19 AM
finance.yahoo.com logoEdited Transcript of ATRC earnings conference call or presentation 27-Jul-17 8:30pm GMT
finance.yahoo.com - July 29 at 3:51 PM
streetinsider.com logoAtriCure Inc. (ATRC) PT Raised to $26 at Needham & Company Following 2Q Beat
www.streetinsider.com - July 28 at 5:24 PM
finance.yahoo.com logoAtriCure, Inc. breached its 50 day moving average in a Bearish Manner : ATRC-US : July 28, 2017
finance.yahoo.com - July 28 at 5:24 PM
americanbankingnews.com logoAtriCure, Inc. (NASDAQ:ATRC) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS
www.americanbankingnews.com - July 28 at 3:33 PM
americanbankingnews.com logoAtriCure, Inc. (ATRC) Updates FY17 Earnings Guidance
www.americanbankingnews.com - July 27 at 11:34 PM
finance.yahoo.com logoAtriCure Reports Second Quarter 2017 Financial Results
finance.yahoo.com - July 27 at 9:02 PM
finance.yahoo.com logoAtriCure reports 2Q loss
finance.yahoo.com - July 27 at 9:02 PM
finance.yahoo.com logoInvestor Network: AtriCure, Inc. to Host Earnings Call
finance.yahoo.com - July 27 at 3:54 PM
americanbankingnews.com logo$44.23 Million in Sales Expected for AtriCure, Inc. (ATRC) This Quarter
www.americanbankingnews.com - July 27 at 11:39 AM
americanbankingnews.com logo-$0.25 EPS Expected for AtriCure, Inc. (ATRC) This Quarter
www.americanbankingnews.com - July 25 at 4:25 PM
americanbankingnews.com logoAtriCure, Inc. (ATRC) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 25 at 11:11 AM
bizjournals.com logoDayton-area health care firm adds to C-suite
www.bizjournals.com - July 20 at 5:40 PM
finance.yahoo.com logoAtriCure to Present at the Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - July 20 at 5:39 PM
americanbankingnews.com logoAtriCure, Inc. (NASDAQ:ATRC) Set to Announce Earnings on Thursday
www.americanbankingnews.com - July 20 at 7:40 AM
streetinsider.com logoAtriCure (ATRC) to Hire Salvatore Privitera as New CTO
www.streetinsider.com - July 19 at 3:49 AM
finance.yahoo.com logoAtriCure Announces Hiring of Chief Technology Officer
finance.yahoo.com - July 18 at 5:44 PM
finance.yahoo.com logoETFs with exposure to AtriCure, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 4:59 PM
finance.yahoo.com logoAtriCure to Announce Second Quarter 2017 Financial Results
finance.yahoo.com - July 6 at 5:29 PM
americanbankingnews.com logo Brokerages Anticipate AtriCure, Inc. (ATRC) Will Post Quarterly Sales of $44.23 Million
www.americanbankingnews.com - July 1 at 9:00 AM
americanbankingnews.com logoAtriCure, Inc. (ATRC) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 30 at 12:32 PM
americanbankingnews.com logoZacks: Brokerages Anticipate AtriCure, Inc. (ATRC) to Announce -$0.25 Earnings Per Share
www.americanbankingnews.com - June 29 at 12:48 PM
americanbankingnews.com logoAtriCure, Inc. (ATRC) Receives Outperform Rating from Leerink Swann
www.americanbankingnews.com - June 16 at 12:34 PM
americanbankingnews.com logoAtriCure, Inc. (ATRC) Raised to Hold at ValuEngine
www.americanbankingnews.com - June 12 at 11:36 PM
americanbankingnews.com logo Analysts Anticipate AtriCure Inc. (ATRC) Will Announce Quarterly Sales of $44.23 Million
www.americanbankingnews.com - June 7 at 11:24 AM
americanbankingnews.com logoReviewing AtriCure (ATRC) and Integra Lifesciences Holdings Corp (IART)
www.americanbankingnews.com - June 5 at 10:14 PM
americanbankingnews.com logoHead to Head Comparison: Invuity (IVTY) and AtriCure (ATRC)
www.americanbankingnews.com - June 5 at 8:46 PM
americanbankingnews.com logoAtriCure Inc. (ATRC) Expected to Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - June 5 at 10:52 AM
americanbankingnews.com logoAtriCure Inc. (ATRC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 5 at 9:15 AM
streetinsider.com logoPiper Jaffray Assumes AtriCure Inc. (ATRC) to Overweight
www.streetinsider.com - May 30 at 12:35 PM
americanbankingnews.com logoPiper Jaffray Companies Initiates Coverage on AtriCure Inc. (ATRC)
www.americanbankingnews.com - May 30 at 10:42 AM
finance.yahoo.com logoAtriCure to Present at the JMP Securities Life Science Conference
finance.yahoo.com - May 18 at 12:03 PM
americanbankingnews.com logoElizabeth D. Krell Sells 10,000 Shares of AtriCure Inc. (ATRC) Stock
www.americanbankingnews.com - May 17 at 7:47 PM
americanbankingnews.com logoAtriCure Inc. (ATRC) Upgraded by TheStreet to C-
www.americanbankingnews.com - May 17 at 6:32 PM
finance.yahoo.com logoETFs with exposure to AtriCure, Inc. : May 12, 2017
finance.yahoo.com - May 12 at 4:16 PM

Social

Chart

AtriCure (ATRC) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff